REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Feb 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Decibel Therapeutics, Inc. (DBTX)
CIK: 0001656536
Period of Report: 2021-02-17

Reporting Person: REGENERON PHARMACEUTICALS, INC. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-17	Common Stock	C	2097314	—	Acquired	2097314	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-17	Series B Preferred Stock	$	C	12500000	Disposed		Common Stock (989299)	Direct
2021-02-17	Series C Preferred Stock	$	C	14000000	Disposed		Common Stock (1108015)	Direct

Footnotes

F1: 1. The Series B Preferred Stock and Series C Preferred Stock converted into shares of common stock of Decibel Therapeutics, Inc. ("Decibel") on an approximately one-for-0.079 basis upon the closing of Decibel's initial public offering, which occurred on February 17, 2021. The Series B Preferred Stock and Series C Preferred Stock had no expiration date. The reported number of shares of underlying common stock and the conversion ratio give effect to Decibel's one-for-5.3 reverse stock split, which became effective on February 5, 2021.